ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Who May Qualify: - Is at least 18 years of age and the local legal age of consent for clinical studies - Has been diagnosed with MG with consistent clinical features per the investigator's clinical judgment - If receiving MG therapy, including nonsteroidal immunosuppressive drugs (NSIDs), corticosteroids, or acetylcholinesterase (AChE) inhibitors either in combination or alone, the participant should receive a stable dosage before master protocol screening Who Should NOT Join This Trial: - Known autoimmune conditions (where your immune system attacks your own body) or any medical condition other than the indication under study that would interfere with an accurate assessment of clinical symptoms of MG or puts the participant at undue risk - Is MGFA (Myasthenia Gravis Foundation of America) Class V Always talk to your doctor about whether this trial is right for you.